Dexcom Gains as NEJM Trial Validates G7 for Type 2 Diabetes Patients Not on Insulin

Landmark NEJM study shows Dexcom G7 reduces A1C and boosts time in range for non-insulin Type 2 diabetes patients, lifting shares.